









Markets
/
Stocks
/
nasdaq-repl
/

Replimune Group Inc

REPL

9.305USD

-0.425-4.37%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

724.00MMarket Cap

LossP/E TTM



Replimune Group Inc

9.305

-0.425-4.37%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Replimune Group Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Replimune Group Inc's Score

Industry at a Glance

Industry Ranking

200 / 501

Overall Ranking

351 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

10.625

Target Price

+9.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Replimune Group Inc Highlights

StrengthsRisks

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -2.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 81.96M shares, decreasing 16.05% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 712.54K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.08.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Replimune Group Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.35, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -2.88, which is -69.94% below the recent high of -0.87 and -254.18% above the recent low of -10.20.

Score

Industry at a Glance

Previous score

8.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 200/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 6.22, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Replimune Group Inc is 12.00, with a high of 22.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.22

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

11.750

Target Price

+20.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Replimune Group Inc

REPL

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.22, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 11.70 and the support level at 5.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.08

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.560

Buy

RSI(14)

66.108

Neutral

STOCH(KDJ)(9,3,3)

62.784

Sell

ATR(14)

1.148

High Vlolatility

CCI(14)

30.577

Neutral

Williams %R

23.806

Buy

TRIX(12,20)

3.830

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

9.989

Sell

MA10

9.289

Buy

MA20

7.152

Buy

MA50

5.893

Buy

MA100

6.845

Buy

MA200

8.703

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 105.00%, representing a quarter-over-quarter decrease of 6.76%. The largest institutional shareholder is PRFDX, holding a total of 10.69M shares, representing 13.69% of shares outstanding, with 2.82% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

11.05M

T. Rowe Price Associates, Inc.

Star Investors

10.69M

-0.35%

BlackRock Institutional Trust Company, N.A.

4.97M

-5.36%

Redmile Group, LLC

4.66M

-4.77%

Forbion Capital Partners

3.91M

The Vanguard Group, Inc.

Star Investors

3.46M

-9.37%

Tang Capital Management, LLC

3.20M

+10.34%

State Street Investment Management (US)

2.45M

+2.28%

Boxer Capital Management, LLC

2.21M

+23.10%

RTW Investments L.P.

2.07M

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.